WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

J ANTIINFECTIVES FOR SYSTEMIC USE

Antiinfectives are also classified in the following groups:

A01AB Antiinfectives and antiseptics for local oral treatment
A02BD Combinations for eradication of Helicobacter pylori
A07A Intestinal antiinfectives
D01 Antifungals for dermatological use
D06 Antibiotics and chemotherapeutics for dermatological use
D07C Corticosteroids, combinations with antibiotics
D09AA Ointment dressings with antiinfectives
D10AF Antiinfectives for treatment of acne
G01 Gynecological antiinfectives and antiseptics
P Antiparasitic products, insecticides and repellents
R02AB Antibiotics
S01/
S02/
S03 Eye and ear preparations with antiinfectives

Even systemically administered antibacterials and antimycotics may be classified in other groups if their target is exclusively local, e.g. the skin - D01 - Antifungals for dermatological use

Inhaled antiinfectives are classified in J.

The DDDs for the antiinfectives are as a main rule based on the use in infections of moderate severity. However, some antiinfectives are only used in severe infections and their DDDs are assigned accordingly. The DDDs assigned are based on daily treatment. The duration of the treatment periods is not taken into consideration. For antiinfectives given in a high initially starting dose followed by a lower daily "maintenance" dose, the DDDs are based on the "maintenance" dose if the total duration of the treat-ment course is more than one week. If, however, the treatment course is 7 days or less, the DDDs are assigned according to the average daily dose i.e. the total course dose divided by the number of treatment days (e.g azithromycin).


J05 ANTIVIRALS FOR SYSTEMIC USE

This group comprises specific antiviral agents, excl. vaccines.

Antivirals for dermatological use, see D06BB.
Antivirals for ophthalmological use, see S01A - Antiinfectives.

Amantadine, which is also used as an antiviral agent, is classified in N04BB.


J05A DIRECT ACTING ANTIVIRALS

This group comprises agents acting directly on the virus.


J05AA Thiosemicarbazones
J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors

Ribavirin is classified in J05AP.

The combinations of ribavirin and peginterferon alfa-2a or peginterferon alfa-2b are classified in L03AB.

The DDDs for aciclovir, valaciclovir and famciclovir are based on the treatment of herpes zoster infections.

The DDD for ganciclovir is based on the treatment of cytomegalovirus infections in immunosuppressed patients.

The DDD for cidofovir is based on the treatment of CMV-retinitis in AIDS patients.

J05AC Cyclic amines

Amantadine is classified in N04 - Anti-Parkinson drugs.

J05AD Phosphonic acid derivatives

The DDD for foscarnet is based on the treatment of CMV-retinitis in AIDS patients.

J05AE Protease inhibitors

The DDDs are based on combination therapy in HIV infections.

The DDDs for atazanavir and fosamprenavir are based on combination therapy with ritonavir as a pharmacokinetic enhancer.

The DDD for saquinavir is based on the dose recommendations for hard capsules.

J05AF Nucleoside and nucleotide reverse transcriptase inhibitors

The DDDs are based on combination therapy in HIV infections.

The DDD for tenofovir disoproxil is 245 mg and is equivalent to 300 mg tenofovir disoproxil fumarat.

The DDDs for entecavir and telbivudine are based on monotherapy in the treatment of chronic hepatitis B virus infections.

J05AG Non-nucleoside reverse transcriptase inhibitors

Vaginal ring with dapiravine for risk reduction of HIV-1 infection is classified in G01AX.

The DDDs are based on combination therapy in HIV infections.

J05AH Neuraminidase inhibitors

All neuraminidase inhibitors are classified here, regardless of formulation.

The DDD of oseltamivir is based on the treatment of influenza.

J05AP Antivirals for treatment of HCV infections

This group includes both single substances and combinations.

The inhalation DDD for ribavirin is based on the treatment of respiratory syncytial viral (RSV) infections in neonates and infants.

J05AR Antivirals for treatment of HIV infections, combinations

Combinations with pharmacokinetic enhancers are classified in this group, regardless of their antiviral effect. Plain products with cobicistat are classified in V03AX.

See list of DDDs for combination products, www.whocc.no.

J05AX Other antivirals

Last updated: 2018-12-13